Clinical efficacy of recombinant human brain natriuretic peptide in treatment of refractory heart failure

ZHANG Bao-qin; BAI Zhi-sheng; QU Jian-hui

doi:10.3969/j.issn.1674-4055.2016.03.20

Abstract：Objective To observe the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) in treatment of refractory heart failure.Methods The patients with refractory heart failure (n=72) were chosen from Apr. 2009 to Jun. 2013, and divided into observation group and control group (eachn=36). The changes of blood pressure (BP), N-terminal pro brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), heart rate (HR) and LVEDd, and adverse reactions were observed in 2 groups before and after treatment for 72 h.Results After treatment for 72 h, the effective rate of ameliorating refractory heart failure was significantly higher in observation group than that in control group (86.1%vs. 52.8%,P<0.05). After treatment, HR decreased significantly in observation group [(84.7±4.3) times/minvs. (80.8±2.7) times/min,P<0.05] and in control group [(85.5±3.0) times/minvs. (80.6±1.8) times/min]. After treatment, the level of NT-proBNP decreased significantly in observation group [(2843.4±611.3) ng/Lvs. (1675.5±446.8) ng/L,P<0.05] and in control group [(2782.0± 688.3) ng/Lvs. (1955.1±404.4) ng/L,P<0.05], which was more significant in observation group (P<0.05). After treatment, LVEF increased significantly in observation group [(37.6±7.9)%vs. (49.8±7.9)%] and control group [(36.9±10.2)%vs. (45.0±9.0)%,P<0.05], which was more significant in observation group (P<0.05). There was no statistical difference in incidence of hypotension between 2 groups (P>0.05).Conclusion The curative effect of rhBNP is good on refractory heart failure, and it can improve significantly hemodynamic parameters without obvious adverse reactions.